3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Motor Activity
2
Substance-Related Disorders
1
Pituitary Neoplasms
1
Opioid-Related Disorders
1
Neurofibromatosis 1
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Acromegaly
1
Interventions
AZD 6244
12
trametinib
4
mirdametinib
2
fludarabine
2
Lasers, Solid-State
2
Inhalation
2
Deoxycholic Acid
2
Acetylcysteine
2
thymoglobulin
1
talimogene laherparepvec
1
omipalisib
1
lorlatinib
1
fludarabine phosphate
1
encorafenib
1
dabrafenib
1
cabozantinib
1
binimetinib
1
abemaciclib
1
Waiting Lists
1
Vincristine
1
Specimen Handling
1
Sirolimus
1
Rituximab
1
Radiation
1
Polidocanol
1
N-monoacetylcystine
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Lovastatin
1
Liquid Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neurofibromatosis 1
×
Dosage Forms
×
1 year
×
Clear all
NCT05309668
2025-12-18
SPRINKLE
AstraZeneca
Phase 1/2
Active not recruiting
36 enrolled
37 charts